The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: A randomized trial

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 400-406

  Ketter, Terence A ^a   Greist, John H ^b   Graham, James A ^c   Roberts, Jeremy N ^d   Thompson, Thomas R ^c   Nanry, Kevin P ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; LAMOTRIGINE; LITHIUM; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUETIAPINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; ARTICLE; BIPOLAR I DISORDER; BULLOUS DERMATITIS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HEADACHE; HEAT RASH; HUMAN; INSOMNIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; NAUSEA; PAPULAR RASH; PRIORITY JOURNAL; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN MANIFESTATION; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; URTICARIA;

EID: 33645780692     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0310     Document Type: Article

References (14)

1. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004;27:173-184
2. Green B. Lamotrigine in mood disorders. Curr Med Res Opin 2003;19:272-277
3. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002;63:1012-1019
4. Messenheimer JA, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-296
5. Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998;25:S14-S18
6. Lamictal [product information]. Research Triangle Park, NC: GlaxoSmithKline; 2005
7. Ketter TA, Wang PW, Chandler RA, et al. Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry 2005;66:642-645
8. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53:1028-1042
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
10. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-171
11. American Psychiatric Association Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000
12. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88
13. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
14. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-441